While Bicara Therapeutics Inc has underperformed by -3.30%, investors are advised to look at stock chart patterns for technical insight.
On May 23, 2025, Wells Fargo Upgraded Bicara Therapeutics Inc (NASDAQ: BCAX) to Equal Weight. A report published by Wells Fargo on April 17, 2025, Initiated its previous ‘Underweight’ rating for BCAX. Wedbush also rated BCAX shares as ‘Outperform’, setting a target price of $31 on the company’s shares in an initiating report dated February 06, 2025. H.C. Wainwright Initiated an Buy rating on December 06, 2024, and assigned a price target of $42. Rodman & Renshaw initiated its ‘Buy’ rating for BCAX, as published in its report on November 05, 2024. Stifel also rated the stock as ‘Buy’.
Analysis of Bicara Therapeutics Inc (BCAX)
In order to gain a clear picture of Bicara Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. Taking into account the quick ratio of the company, currently set at 24.62, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 813.47K can be a very valuable indicator of volatility for BCAX stock. On a monthly basis, the volatility of the stock is set at 13.01%, whereas on a weekly basis, it is put at 2.57%, with a loss of -23.13% over the past seven days. Furthermore, long-term investors anticipate a median target price of $32.60, showing growth from the present price of $9.67, which can serve as yet another indication of whether BCAX is worth investing in or should be passed over.
How Do You Analyze Bicara Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 39.92%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 62.30% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BCAX shares are owned by institutional investors to the tune of 62.30% at present.
